Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study

Diabetes, Obesity and Metabolism

Volumn 9, Issue 2, 2007, Pages 166-174

  Garber, A J ^a   Schweizer, A ^b   Baron, M A ^b   Rochotte, E ^b   Dejager, S ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dipeptidyl peptidase 4; GLP 1; Incretin hormones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS OF COVARIANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 33846828660     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00684.x     Document Type: Article

References (23)

1. Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
2. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
3. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423-428.
4. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-698.
5. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
6. Burkey BF, Li X, Bolognese L et al. Combination treatment of a DPP-IV inhibitor NVP-LA237 with pioglitazone completely normalized glucose tolerance in adult obese zucker rats. Diabetes 2002; 51 (Suppl. 2): A338-A339.
7. van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
8. Hochberg Y, Tamhane AC. Some theory of multiple comparison procedures for fixed-effects linear models In: Y. Hochberg, A. C. Tamhane (Eds.). Multiple comparison procedures. John Wiley & Sons. New York 1987; pp; 19-71.
9. Dejager S, Baron MA, Razac S, Foley JE, Dickinson S, Schweizer A. Efficacy of vildagliptin in drug-naive patients with type 2 diabetes. Diabetologia 2006; 49 (Suppl. 1): 479-480.
10. Garber A, Camisasca RP, Ehrsam E, Collober-Maugeais C, Rochotte E, Lebeaut A. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006; 55 (Suppl. 1): A29.
11. Takeda Pharmaceuticals. Actos ® (Pioglitazone Hydrocholoride Tablets) Prescribing Information. 2002. Lincolnshire, IL, Takeda Pharmaceuticals America, Inc.
12. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-263.
13. Rosenstock J, Baron MA, Schweizer A, Mills D, Dejager S. Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM). Diabetes 2006; 55 (Suppl 1): A133 (Abstract 557-P).
14. Baron MA, Rosenstock J, Bassiri B et al. Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes. Diabetologia 2006; 49 (Suppl. 1): 485-486.
15. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102: 9406-9411.
16. Staels B. Fluid retention mediated by renal PPARγ. Cell Metab 2005; 2: 77-78.
17. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104.
18. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.
19. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 2210-2219.
20. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006; 15: 243-250.
21. Jovanovic L, Hassman DR, Gooch B et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004; 63: 127-134.
22. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-1547.
23. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-1547.